A open-label stratified phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance

Trial Profile

A open-label stratified phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2011

At a glance

  • Drugs Bortezomib (Primary) ; Aromatase inhibitors; Selective estrogen receptor modulators
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms HOBO
  • Most Recent Events

    • 24 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top